ARRAY BIOPHARMA INC — Operating Income by Fiscal Year
9 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/3fe9443f-31b6-4a00-91d0-766432167991/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2018 | $-129.9M | 2017-07-01 – 2018-06-30 | evidence 0001100412-18-000026 |
| FY 2017 | $-102.1M | 2016-07-01 – 2017-06-30 | evidence 0001628280-17-008555 |
| FY 2016 | $-82.2M | 2015-07-01 – 2016-06-30 | evidence 0001100412-16-000048 |
| FY 2015 | $3.3M | 2014-07-01 – 2015-06-30 | evidence 0001100412-15-000023 |
| FY 2014 | $-75.6M | 2013-07-01 – 2014-06-30 | evidence 0001100412-14-000048 |
| FY 2013 | $-39.5M | 2012-07-01 – 2013-06-30 | evidence 0001100412-13-000025 |
| FY 2012 | $-11.0M | 2011-07-01 – 2012-06-30 | evidence 0001047469-12-008381 |
| FY 2011 | $-36.8M | 2010-07-01 – 2011-06-30 | evidence 0001047469-12-008381 |
| FY 2010 | $-64.1M | 2009-07-01 – 2010-06-30 | evidence 0001047469-12-008381 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).